Aldeyra Therapeutics (ALDX) AI Stock Analysis

• Market Cap: $395.27M
• Dividend Yield: N/A
• Average Volume (3M): 495.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.52
• Revenue Growth: N/A
• EPS Growth: -47.28%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 59,708,652
• 10 Day Avg. Volume: 773,763
• 30 Day Avg. Volume: 495,280
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -7.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.50
• Price Target Upside: 51.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Aldeyra Therapeutics' financial performance highlights significant risks due to lack of revenue and ongoing losses, albeit mitigated by strong cash reserves. Technical analysis shows some positive momentum, but the valuation reflects the typical high-risk nature of biotech stocks in development stages. Successful product development and market entry are crucial for future stability and growth.

Positive Factors

FDA Approval

Reproxalap has met FDA draft guidance requirements of 2 well-controlled studies for signs and symptoms of dry eye disease.

Partnership Opportunities

Approval would likely lead AbbVie to exercise the option to co-commercialize reproxalap, triggering a $100M milestone payment to Aldeyra.

Negative Factors

Manufacturing Risks

A manufacturing CRL would jeopardize the option for reproxalap, despite double CRLs being rare for novel drugs.

Aldeyra Therapeutics Business Overview & Revenue Model

Company Description

Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company engaged in the development of innovative therapies for immune-mediated diseases. The company's core focus is on the identification and development of drugs that alleviate inflammation and other related conditions by targeting reactive aldehyde species, which are implicated in numerous diseases. Aldeyra's product pipeline includes treatments for conditions such as dry eye disease, allergic conjunctivitis, and non-infectious anterior uveitis.

How the Company Makes Money

Aldeyra Therapeutics primarily makes money through the development and commercialization of its pharmaceutical products. Its revenue model is based on the successful progression of its drug candidates through clinical trials, regulatory approval, and eventual sales in the healthcare market. The company may also enter into licensing agreements and partnerships with larger pharmaceutical companies to enhance development and distribution capabilities, which can provide upfront payments, milestone payments, and royalties. Additionally, Aldeyra might receive funding through grants, collaborations, or equity investments to support its ongoing research and development activities.

Aldeyra Therapeutics Financial Statement Overview

Summary

Aldeyra Therapeutics shows a challenging financial position with consistent losses and no revenue. The strong liquidity position provides a buffer, but the lack of revenue and high R&D costs underscore sustainability risks unless successful commercialization occurs.

Income Statement

Aldeyra Therapeutics has consistently reported zero revenue over recent years, indicating no commercialized products. The company shows significant negative EBIT and net income, reflecting high R&D and operational costs typical for a biotech firm in its developmental phase. The absence of revenue and persistent losses highlight a challenging financial situation with potential risks related to sustainability.

Balance Sheet

The balance sheet shows a strong liquidity position with substantial cash reserves compared to debt, resulting in negative net debt. The company maintains a relatively healthy equity ratio, indicating moderate financial leverage. However, continuous losses impact shareholder equity negatively over time, which could be a concern if no revenue streams are established.

Cash Flow

Cash flow analysis reveals ongoing negative operating and free cash flows, typical for early-stage biotech companies focusing on R&D. The negative free cash flow growth rate and reliance on financing activities suggest the company is burning cash without generating operational income, posing a risk if external funding sources dry up.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-262.78K	-258.71K	-264.18K	-56.22K
	EBIT
-60.12T	-42.79M	-62.68M	-56.22M	-36.42M
	EBITDA
-60.12T	-35.21M	-60.07M	-55.77M	-36.07M
	Net Income Common Stockholders
-55.85T	-37.54M	-61.37M	-59.25M	-37.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.00T>	142.82M	174.30M	229.79M	77.86M
	Total Assets
10.00T>	148.33M	181.29M	233.14M	83.35M
	Total Debt
15.30M	15.66M	16.08M	15.86M	15.33M
	Net Debt
-39.22M	-127.17M	-128.34M	-213.93M	-62.53M
	Total Liabilities
33.60T	28.53M	30.28M	27.40M	23.84M
	Stockholders Equity
71.00T	119.80M	151.01M	205.74M	59.51M
Cash Flow		Free Cash Flow
-43.21T	-30.33M	-56.65M	-42.56M	-37.49M
	Operating Cash Flow
-43.21T	-30.33M	-56.64M	-42.56M	-37.49M
	Investing Cash Flow
-44.92T	30.00M	-29.95M	-7.81K	29.02M
	Financing Cash Flow
-171.42B	-1.27M	1.22M	194.50M	41.90M

Aldeyra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALDX, the sentiment is Positive. The current price of 6.92 is above the 20-day moving average (MA) of 6.37, above the 50-day MA of 5.66, and above the 200-day MA of 4.96, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 63.37 is Neutral, neither overbought nor oversold. The STOCH value of 91.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALDX.

Aldeyra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OCUL	52 Neutral	$1.22B	―	-95.21%	―	9.03%	-25.00%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
EYPT	48 Neutral	$487.29M	―	-43.42%	―	-5.97%	-25.87%
ALDX	44 Neutral	$395.27M	―	-58.54%	―	―	-47.28%
KOD	44 Neutral	$195.76M	―	-78.57%	―	―	29.63%
XOMA	42 Neutral	$241.55M	―	-31.41%	―	389.82%	-22.66%
ADVM	42 Neutral	$91.53M	―	-76.26%	―	-72.22%	51.95%